21 octubre 2015
Recent research has yielded new information about immune responses associated with — and potentially responsible for — protection from HIV infection, providing leads for new strategies to develop an HIV vaccine. Results from the RV144 trial, reported in 2009, provided the first signal of HIV vaccine efficacy: a 31 percent reduction in HIV infection among vaccinees. Since then, an international research consortium has been searching for molecular clues to explain why the vaccine showed this modest protective effect.
http://www.sciencedaily.com/releases/2015/10/151021170821.htm
